GSK's (GSK.US) "first-in-class" antibody therapy Nucala met the primary endpoint in its Phase 3 trial

Market VisionFriday, Sep 6, 2024 9:40 pm ET

1min read

GlaxoSmithKline (GSK.US) announced positive results from its Phase 3 MATINEE clinical trial of Nucala (mepolizumab), a "first-in-class" antibody therapy, in patients with chronic obstructive pulmonary disease (COPD). The trial results will support GSK's discussions with regulators to submit an application for the extension of Nucala's indication.

The MATINEE trial met its primary endpoint, with Nucala added to an inhaled maintenance therapy, significantly reducing the annual rate of moderate/severe disease exacerbations compared to placebo, with a clinically meaningful difference.

Nucala was first approved in the US in 2015 for the treatment of severe asthma with an eosinophilic phenotype. It is a monoclonal antibody targeting IL-5, developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.